Emerging Weight-Loss Drugs Spark Excitement and Competition in Retail Market
TL;DR
Retail investors have flocked to buy shares of Eli Lilly after the U.S. pharmaceutical company received approval for its weight-loss drug, Zepbound. Daily net purchases reached a more than two-year high of $14.4 million on November 8, signaling a resurgence of interest in the healthcare sector. Eli Lilly and Novo Nordisk, both leaders in the potential $100 billion obesity treatment market, have attracted retail investors who are now catching up with institutional investors. Despite a decline in overall retail flows to U.S. exchanges, interest in weight-loss drugmakers remains strong.
Topics:healthbusiness#business#eli-lilly#healthcare-sector#novo-nordisk#retail-investors#weight-loss-drug
- Retail investors crowd into Eli Lilly after weight-loss drug approval Reuters
- Approval of Tirzepatide for Treating Obesity 'Exciting' Medscape
- New Ozempic Competitor for Weight Loss May Be Better Tolerated Best Life
- What the new obesity drug Zepbound means for the Black community TheGrio
- Mounjaro has been authorised for weight loss in the UK – here's how it compares to Wegovy The Conversation Indonesia
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Reuters